- Home
- THCH vs VOR Comparison
THCH vs VOR Comparison
Compare THCH & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THCH
- VOR
- Stock Information
- Founded
- THCH 2018
- VOR 2015
- Country
- THCH China
- VOR United States
- Employees
- THCH N/A
- VOR N/A
- Industry
- THCH Blank Checks
- VOR Biotechnology: Pharmaceutical Preparations
- Sector
- THCH Finance
- VOR Health Care
- Exchange
- THCH Nasdaq
- VOR Nasdaq
- Market Cap
- THCH 84.8M
- VOR 22.1M
- IPO Year
- THCH N/A
- VOR 2021
- Fundamental
- Price
- THCH $2.91
- VOR $1.06
- Analyst Decision
- THCH
- VOR Buy
- Analyst Count
- THCH 0
- VOR 7
- Target Price
- THCH N/A
- VOR $3.77
- AVG Volume (30 Days)
- THCH 17.2K
- VOR 36.3M
- Earning Date
- THCH 06-24-2025
- VOR 08-07-2025
- Dividend Yield
- THCH N/A
- VOR N/A
- EPS Growth
- THCH N/A
- VOR N/A
- EPS
- THCH N/A
- VOR N/A
- Revenue
- THCH $187,384,526.00
- VOR N/A
- Revenue This Year
- THCH N/A
- VOR N/A
- Revenue Next Year
- THCH N/A
- VOR N/A
- P/E Ratio
- THCH N/A
- VOR N/A
- Revenue Growth
- THCH N/A
- VOR N/A
- 52 Week Low
- THCH $2.15
- VOR $0.13
- 52 Week High
- THCH $5.15
- VOR $1.80
- Technical
- Relative Strength Index (RSI)
- THCH 50.04
- VOR 89.72
- Support Level
- THCH $2.58
- VOR $0.29
- Resistance Level
- THCH $2.97
- VOR $1.26
- Average True Range (ATR)
- THCH 0.16
- VOR 0.13
- MACD
- THCH 0.00
- VOR 0.10
- Stochastic Oscillator
- THCH 47.64
- VOR 81.46
About THCH TH International Limited Ordinary shares
TH International Ltd is the parent company of the franchise of Tim Hortons coffee shops and has the rights to operate Tim Hortons coffee shops in mainland China, Hong Kong, and Macau. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. The Company operated under single reportable segment, Tim Hortons. The company's revenue is derived from its operations in the PRC.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.